Prothena Corporation plc (NASDAQ: PRTA) was founded in 2012 and is headquartered in Dún Laoghaire, Ireland. It has 96 full-time employees. It is a late-stage clinical stage biotechnology company that focuses on the treatment of protein misfolding (protein misfolding). ) Or the discovery, development and commercialization of new immunotherapies for cell adhesion diseases.
Prothena Corporation (PRTA):
Prothena Corporation plc is a clinical-stage biotechnology company focusing on the discovery, development and commercialization of new antibodies for the treatment of various protein misfolding or cell adhesion-related diseases, mainly targeting disease-caused proteins and developing therapeutic clones Antibody drugs. Candidate products include:
- NEOD001-a monoclonal antibody used to treat AL amyloidosis, currently in phase III clinical trials;
- PRX002-Phase Ib clinical trials for the treatment of Parkinson’s disease and other related synuclein diseases have been completed;
- PRX003-is a monoclonal antibody used to treat psoriasis and other inflammatory diseases, currently in the Ib clinical trial stage;
- PRX004-is a monoclonal antibody, currently in the preclinical development stage.
Prothena Corporation has signed licensing, development and commercialization agreements with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target α-synuclein.